Loading...
 
Back to the list
Mediterr J Rheumatol 2020;31(Suppl 2):259-67
Article Links
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARS-CoV-2): What is the Evidence?
Eleftherios Pelechas, Vassiliki Drossou, Paraskevi V. Voulgari, Alexandros A. Drosos
Authors Information

Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Eleftherios Pelechas, Vassiliki Drossou, Paraskevi V. Voulgari, Alexandros A. Drosos

Keywords: SARS-CoV-2, COVID-19, cytokine storm, ACE2 receptor, spike protein, IL-6, hydroxychloroquine, tocilizumab, colchicine
References
  1. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature 2020;10.1038/s41586-020-2223-y.
  2. Dai H, Zhang X, Xia J, Zhang T, Shang Y, Huang R, et al. High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China. Int J Infect Dis 2020;S1201-9712(20)30218-6.
  3. Cohen FS. How viruses invade cells. Biophys J 2016;110(5):1028-32.
  4. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol 2020;41.
  5. Centres for Disease Control and Prevention. Morbidity and Mortality Weekly Report, Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm. Accessed on 10.04.2020.
  6. World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Scientific brief 29 March 2020. https://www.who.int/publications-detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations. Accessed on 10.04.2020.
  7. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;Epub 2020 Mar 30.
  8. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-69.
  9. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a Clinically proven Protease Inhibitor. Cell 2020;181:1-10.
  10. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 2020;38(2):175-80.
  11. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.  medRxiv 2020.03.22.20040758.
  12. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.
  13. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71(15):732-9.
  14. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020 Apr 13. Doi: 10.1001/jama.20206019.
  15. Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020;50(4):384.
  16. Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev 2020;19(7):102566.
  17. Markatseli TE, Theodoridou A, Zakalka M, Koukli E, Triantafyllidou E, Tsalavos S, et al. Persistence and adherence during the first six months of tocilizumab treatment among rheumatoid arthritis treatment among rheumatoid arthritis patients in routine clinical practice in Greece. Results from the single arm REMISSION II study (NCT01649817). Mediterr J Rheumatol 2019;30(3):177-85.
  18. Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2019;15:1073-9.
  19. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4.
  20. Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis 2020;79(9):1143-51.
  21. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol 2020;72(7):1059-63.
  22. Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 2020;pii:S0923-7534(20)36387-0.
  23. Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 2020;4(7):1307-10.
  24. Mihai C, Dobrota R, Schroder M, Garaiman A, Jordan S, Becker MO, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 2020;pii:annrheumdis-2020-217442.
  25. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020. Doi: 10.1002/jmv.25801.
  26. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicenter study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38(3):529-32.
  27. Campins L, Boixeda R, Perez-Cordon L, Aranega R, Lopera C, Force L. Early tocilizumab treatment could improve survival among COVID-19 patients. Clin Exp Rheumatol 2020;38(3):578.
  28. Conrozier T, Lohse A, Balblanc JC, Dussert P, Royer PY, Bossert M, et al. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol 2020;38(4):742-7.
  29. Iliou C, Papagoras C, Tsifetaki N, Voulgari PV, Drosos AA. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol 2013;31(1):47-52.
  30. Adam Monteagudo L, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol 2020. Doi: 10.1002/acr2.11135.
  31. Moutsopoulos HM, Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Ann Rheum Dis 2020;79(9):1253-4.
  32. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020;20(4):400-2.
  33. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395(10223):e30-e31.
  34. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. J Infect 2020;81(2):318-56.
  35. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2020;7(3):ofaa102.
  36. Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, et al. The Greek study in the Effects of Colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol 2020;pii:S1109-9666(20)30061-0.
  37. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect 2020;81(1):e13-e20.
  38. Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia 2020;34(6):1503-11.
  39. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature 2020;582(7813):469.
  40. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the management of Rheumatic disease in adult patients during the COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020 Apr 29.
  41. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2020;2(5):e250-e253.
  42. Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2020;2(9):e549-e556.
  43. Recommendations Regarding COVID 19 infection in Rheumatic Patients in Greece – The Greek Rheumatology Society and Professional Association of Rheumatologists – ERE-EPERE. Mediterr J Rheumatol 2020;31(1):6-7.
  44. Del Papa N, Sambataro G, Minniti A, Pignataro F, Caporali R. Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients. Autoimmun Rev 2020;19(7):102558.
  45. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991;9(6):621-4.
  46. Gocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen. Lancet 1970;2:1149-53.
  47. Haq SA, Pagnoux C. Infection-associated vasculitides. Int J Rheum Dis 2019;22(Suppl. 1):109-15.